Skip to content
OncoAlert home
  • Newsletter
  • News
  • Congresses
  • Tumor sites
  • Colloquium
  • Series
  • About
Subscribe
MenuClose
  • Newsletter
  • News
  • Congresses
    • On demandESMO 2026 highlights
    • 4Sight
    • On The Go
    • Podium2Screen
    • Congress tracker
    • Past coverage
    • Recent coverage

      • ESMO 2025, Berlin
      • ASCO 2025, Chicago
  • Tumor sites
    • Breast
    • Lung and thoracic
    • Genitourinary
    • Gastrointestinal
    • More tumor sites

      • Gynecologic
      • Hematologic
      • Melanoma and skin
      • Head and neck
      • Sarcoma
    • Across disciplines

      • Radiation oncology
      • Supportive care
      • Geriatric oncology
  • Colloquium
    • The 2026 Colloquium
    • Watch the talks
    • Every Colloquium
    • The 2026 program

      • Genitourinary
      • Breast
      • Gastrointestinal
      • Gynecologic
      • Lung and supportive care
      • Melanoma, hematology and more
      • How I treat when options are limited
  • Series
    • OncoAlert Horizons
    • Oncology Here & Now
    • Listen to Oncology Here & Now

      • Apple Podcasts
      • Spotify
      • Amazon Music
      • YouTube
  • About
    • About OncoAlert
    • Faculty
    • Contact
ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlightsSubscribe to the newsletter
  • On demandESMO 2026 highlights
  • 4Sight
  • On The Go
  • Podium2Screen
  • Congress tracker
  • Past coverage

Recent coverage

  • ESMO 2025, Berlin
  • ASCO 2025, Chicago
ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlights
  • Breast
  • Lung and thoracic
  • Genitourinary
  • Gastrointestinal

More tumor sites

  • Gynecologic
  • Hematologic
  • Melanoma and skin
  • Head and neck
  • Sarcoma

Across disciplines

  • Radiation oncology
  • Supportive care
  • Geriatric oncology
NADIM: five-year outcomesPerioperative chemotherapy plus nivolumab in resectable stage IIIA NSCLC: 5-year progression-free survival of 65%.Latest highlight, from The Lancet Oncology
  • The 2026 Colloquium
  • Watch the talks
  • Every Colloquium

The 2026 program

  • Genitourinary
  • Breast
  • Gastrointestinal
  • Gynecologic
  • Lung and supportive care
  • Melanoma, hematology and more
  • How I treat when options are limited
The OncoAlert Colloquium emblemThe OncoAlert ColloquiumThe year in review in oncology, one tumor group a day. Free for oncology professionals.
  • OncoAlert Horizons
  • Oncology Here & Now

Listen to Oncology Here & Now

  • Apple Podcasts
  • Spotify
  • Amazon Music
  • YouTube
The newest Horizons discussionAdjuvant treatment challenges in early HR+/HER2− breast cancer, with Dr. Sibylle Loibl and Dr. Rupert Bartsch.
  • About OncoAlert
  • Faculty
  • Contact

THE COMPLETE ESMO26 NEWSLETTER : Every key trial from Madrid, curated by oncologists

The OncoAlert Newsletter, October 29, 2026. ESMO 2026, after the congress.

Earlier issueWhat’s changing in oncology? Giredestrant, NGS, HER2-targeted therapy, FDA approvals & moreEvery issue

The week in oncology, in your inbox

The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.

How we use your details

OncoAlert

The OncoAlert Network is a registered non-profit NGO, founded in 2019 as a voluntary network of oncologists and patient advocates.

OncoAlertNetwork@OncoAlert360.com

Coverage

  • News
  • The newsletter
  • Congresses
  • 4Sight
  • The Colloquium
  • OncoAlert Horizons
  • Oncology Here & Now

The network

  • Faculty
  • About OncoAlert
  • How we are funded
  • Contact

Follow

  • X
  • LinkedIn
  • YouTube
  • Instagram
  • Facebook

© 2026 The OncoAlert Network

Privacy